NCT03620123: A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
- State
- Completed
- Phase
- Phase 2
- People
- 54 taking part
- Started
- 16 Jul 2018
- Primary completion
- 20 Jun 2021
- Arms
- Nivolumab and Ipilimumab
- Results
- None posted
- 16 Jul 2018: Trial started
- 8 Aug 2018: Trial registered
- 19 Jun 2022: Trial completed